Phar 7.14(3)(b)3.b.b. The drug product or device includes a description of the drug product or device on the prescription label. Phar 7.14(3)(b)3.c.c. The pharmacist shows the patient or patient’s agent the drug product or device and provides a monograph that includes a description of the drug product or device. Phar 7.14(4)(a)(a) A minimum of 5% of each pharmacy product verification technician’s verifications shall be audited by a licensed pharmacist. The accuracy of each pharmacy product verification technician shall be tracked individually. Phar 7.14(4)(b)(b) A record of each pharmacy product verification technician-check-pharmacy technician audit shall include all of the following: Phar 7.14(4)(c)(c) On a quarterly basis, the supervising pharmacist shall perform an assessment of each pharmacy product verification technician’s previous 12 months accuracy and correctness of pharmacy product verifications including a review of the quality assurance log. Phar 7.14(4)(d)(d) A pharmacy product verification technician shall be revalidated if the individual fails to maintain a product verification accuracy rate of 99.8% based on the quarterly assessment of the previous 12 months or has not performed verifications within the last 6 months. Phar 7.14(5)(5) Policies and procedures. Each pharmacy shall maintain policies, procedures, and training materials for the pharmacy product verification by technicians which shall be made available to the board upon request. Phar 7.14(6)(a)(a) Each pharmacy shall maintain for 5 years the following records: Phar 7.14(6)(a)1.1. All validation records of each pharmacy product verification technician that include the dates that the validation occurred, the number of product verifications performed, the number of product verification errors, and overall accuracy rate. Phar 7.14(6)(a)2.2. Documentation indicating accepting responsibility for compliance with this section, signed and dated by both the managing pharmacist and supervising pharmacist, indicating the name of the supervising pharmacist, and the dates the supervision responsibilities begin and end. Phar 7.14(6)(b)(b) Records shall be made available to the board upon request. Phar 7.14 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21; corrections in (2) (e) made under ss. 13.92 (4) (b) 12. and 35.17, Stats., and correction in (2) (c) 6. (intro.), (4) (b) 7. made under s. 35.17, Stats., Register December 2020 No. 780; EmR2303: emerg. am. (title), (1) (a), (b), (d), (2) (intro.), r. (2) (a), am. (2) (b), (c) 3., 6., (d) 1., 2., (e), (3) (a) (intro.), (b), (4) (a), (b) (intro.), 1., (c), (d), (5), (6) (a) 1., 2., eff. 2-3-23; CR 23-072: r. and recr. (title), am. (1) (a), (b), (d), (2) (intro.), r. (2) (a), am. (2) (b), (c) 3., 6., (d) 1., 2., (e), (3) (a) (intro.), (b) (intro.), 1., (c), (d), (5), (6) (a) 1., 2. Register August 2024 No. 824, eff. 9-1-24. Phar 7.15(2)(2) A link to the 100 most commonly prescribed generic drug product equivalents as determined by the board, shall be maintained on the department’s website as required in s. 450.13 (5m) (b), Stats. Phar 7.15 NoteNote: Copies of the required consumer disclosures are located on the Department of Safety and Professional Service’s website: https://dsps.wi.gov. Phar 7.15(3)(3) Pursuant to s. 450.13 (5m) (c), Stats., each pharmacy shall maintain and make available to the public a list of the drugs from the list in sub. (2) that are available for purchase at that pharmacy. The list shall be updated monthly, with all of the following information included: